Shares of CareDx Inc (Symbol: CDNA) rose to $26.18, surpassing the average analyst 12-month target price of $25.80, as of the most recent trading session. Analysts are now faced with the decision to either downgrade based on valuation or adjust their target prices higher in response to the increased stock value.
According to data from Zacks, the analyst target distribution shows a range with one target as low as $21.00 and another as high as $28.00, resulting in a standard deviation of $2.863. Currently, there are three strong buy ratings, five hold ratings, and no sell ratings, maintaining an average rating of 2.25, where 1 is a strong buy and 5 is a strong sell.
This upward movement has prompted investors to reassess the valuation of CareDx Inc to determine if the price will continue to rise or if it is time to sell some shares.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
